Characterization of T‐DM1‐resistant breast cancer cells

Characterization of T‐DM1‐resistant breast cancer cells

Abstract The development of targeted therapies has drastically improved the outcome of patients with different types of cancer. T‐DM1 (trastuzumab‐emtansine) is an antibody‐drug conjugate used for the treatment of HER2‐positive breast cancer combining the FDA approved mAb (monoclonal antibody) trast...

Full description

Bibliographic Details
Main Authors: Juliette Sauveur, Louise Conilh, Sabine Beaumel, Kamel Chettab, Lars‐Petter Jordheim, Eva‐Laure Matera, Charles Dumontet
Format: Article
Language:English
Published: Wiley 2020-08-01
Series:Pharmacology Research & Perspectives
Subjects:
breast cancer
HER2
resistance
SLC transporters
T‐DM1
tubulin
Online Access:https://doi.org/10.1002/prp2.617

Internet

https://doi.org/10.1002/prp2.617

Similar Items